Injectables

When to start, how often to repeat, and what the word preventative is actually describing. The mechanism is well understood; most of the confusion is about scheduling, and most of the marketing is about starting earlier.

Last reviewed 15 September 2026

The brand on the syringe is the least useful thing about a filler treatment. What decides how it looks, how long it lasts and whether it can be undone is which region it went into and which layer it was placed in. Here is the map.

Last reviewed 15 September 2026

A prospective multicenter study in the Aesthetic Surgery Journal followed patients treated with a next-generation poly-L-lactic acid biostimulator in the nasolabial folds for a year, reporting effectiveness, satisfaction and safety. Biostimulators are a different treatment from hyaluronic acid rather than a longer-lasting version of it: they deposit a material the body answers by making collagen, so the result builds over months and fades over years. Durability data therefore matters more here than it does for a gel that dissolves.

Aesthetic surgery journal, “Effectiveness, Patient Satisfaction, and Safety of a Next-generation PLLA Collagen Biostimulator for Nasolabial Fold Augmentation: 12-month Results of a Prospective Multicenter Study.” — read the original

Read the full guide: Which Filler Goes Where — and Why the Brand Matters Less Than the Plane →

A randomized, double-blind trial in the Aesthetic Surgery Journal mapped injection points and escalating doses for botulinum toxin in the lower face. The lower face is where the muscles are doing more work than most people realize, and where a few units in the wrong place changes a smile rather than a line. Mapped dosing studies are how that becomes a technique rather than an individual injector's preference.

Aesthetic surgery journal, “Injection Mapping and Dose Escalation For Botulinum Toxin Treatment on the Lower Face: A Randomized, Double-blind Clinical Trial.” — read the original

Read the full guide: Botox Timing: Starting, Spacing, and What “Preventative” Really Buys You →

A review in the Aesthetic Surgery Journal examined forty-six U.S. civil cases involving injectable fillers between 1967 and 2025. Verdicts split almost evenly overall, and autologous fat, hyaluronic acid and biostimulators were implicated in roughly equal numbers. Two findings stand out: cases arising from med-spa procedures produced a plaintiff verdict every time, against forty-seven percent in private clinics and hospitals, and cases involving products without regulatory approval did the same. Neither the injector's credentials nor the severity of the complication predicted the outcome on its own.

Aesthetic surgery journal, “Litigating Filler Complications: Five Decades of Legal Outcomes in the United States.” — read the original

Read the full guide: Which Filler Goes Where — and Why the Brand Matters Less Than the Plane →